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ABSTRACT
Although adverse effects and glucocorticoid resistance cripple their chronic 
use, glucocorticoids form the mainstay therapy for acute and chronic inflammatory 
disorders, and play an important role in treatment protocols of both lymphoid 
malignancies and as adjuvant to stimulate therapy tolerability in various solid tumors. 
Glucocorticoid binding to their designate glucocorticoid receptor (GR), sets off a 
plethora of cell-specific events including therapeutically desirable effects, such as cell 
death, as well as undesirable effects, including chemotherapy resistance, systemic 
side effects and glucocorticoid resistance. In this context, selective GR agonists 
and modulators (SEGRAMs) with a more restricted GR activity profile have been 
developed, holding promise for further clinical development in anti-inflammatory 
and potentially in cancer therapies. Thus far, the research into the prospective 
benefits of selective GR modulators in cancer therapy limped behind. Our review 
discusses how selective GR agonists and modulators could improve the therapy 
regimens for lymphoid malignancies, prostate or breast cancer. We summarize our 
current knowledge and look forward to where the field should move to in the future. 
Altogether, our review clarifies novel therapeutic perspectives in cancer modulation 
via selective GR targeting.
INTRODUCTION
Therapeutic administration of glucocorticoids (GCs) 
is frequently applied to combat inflammatory, immune 
and allergic disorders, brain edema, shock and various 
blood cancers [1-4]. However, in malignancies the effect 
of GCs is ambiguous; it has an anti-cancer effect in most 
hematological malignancies [5-8], yet in solid tumors 
GCs have been shown to inhibit as well as promote tumor 
progression [9-21]. Recent advances in the development of 
selective glucocorticoid receptor agonists and modulators 
(SEGRAMs) have yielded several compounds which bind 
to GR yet exert a different, more specific, action radius 
as compared to classic GCs [3, 22-30]. In the light of this 
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development, some of these SEGRAMs have also been 
studied in the context of malignancies [27, 30-45]. In this 
article we will review what is currently known about the 





In its unliganded state, the glucocorticoid receptor 
(GR) is a predominately cytoplasmic protein and its 
ligand-binding conformation is maintained by its 
chaperoning partners in a large multi-protein complex. 
Nonetheless, GR is able to shuttle between the nucleus 
and the cytoplasm [46, 47]. The ligand-bound GR is 
subject to a conformational change and subsequently 
dissociates from the chaperoning complex. Ligand-bound 
GR is guided to the nucleus where it can fuel or inhibit 
the expression of specific genes via different mechanisms, 
including binding to glucocorticoid-responsive elements 
(GREs) in the genes’ promoter regions and interacting 
with other DNA-bound transcription factors, as such 
influencing gene expression (Figure 1) [48]. Thus, GCs 
stimulate the expression of anti-inflammatory proteins, 
metabolic gene products and certain pro-apoptotic 
proteins [48-51]. They can also inhibit the transcription 
of pro-inflammatory proteins (e.g. cytokines, enzymes 
and adhesion molecules) and certain anti-apoptotic 
proteins through a number of different mechanisms [49-
52]. Besides these GR-mediated genomic mechanisms, 
non-genomic GR-mediated mechanisms have been 
described involving membrane-modulating effects of 
GCs, modulation of signaling pathways by membrane-
associated GRs, cytosolic GRs and mitochondrial GRs 
[53-58]. 
Figure 1: Genomic and non-genomic mechanisms of GR-mediated signaling. Classical GCs such as dexamethasone can enter 
the cell via passive diffusion and bind to GR. Upon GC binding, GR is released from the multiprotein complex and can execute either 
genomic or non-genomic mechanisms. The genomic mechanisms include transactivation, promoting transcription of target genes, and 
transrepression, inhibiting transcription factor (TF)-driven gene expression. The non-genomic mechanisms consist of GCs modulating 
cell membranes, membrane-bound GR, cytosolic and membrane-bound GR modulating signaling pathways and GR translocation into 
mitochondria. The SEGRAM-driven GR can, similar to classical GCs, translocate to the nucleus and repress TF-driven (NF-κB- and/or 
AP-1) driven gene expression, but not (or to a lesser extent) result in the upregulation of GRE-mediated genes such as GILZ. How these 
SEGRAMs affect non-genomic GR-mediated mechanisms such as kinase activities is unknown. 
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CANCER MODULATION VIA 
DIRECT OR INDIRECT EFFECTS OF 
GLUCOCORTICOIDS
GCs have a variety of cell-specific effects on cancer 
cells (Table 1). In hematological malignancies GCs can 
have anti-cancer effects [7, 50, 59]. However, in solid 
tumors the in vitro and in vivo data are controversial. On 
the one hand, it has been shown that GCs inhibit apoptosis 
and prevent chemotherapy-induced apoptosis in most solid 
malignancies [9-12, 16, 17], thereby stimulating tumor 
progression as indicated by an increased likelihood of 
metastasis in breast cancer patients [13, 14] or increased 
risks of skin cancer among users of systemic GCs [15]. 
Also an elevated risk of non-hodgkin lymphoma was 
seen among these users of systemic GCs [15]. These 
results were confirmed by in vitro and in vivo data 
obtained with various human carcinoma cell lines and 
mouse tumor xenografts [12, 16]. On the other hand, GCs 
have also been identified as a chemosensitizer [10, 60, 
61]. Similarly, in prostate cancer GCs can either inhibit 
tumor growth or induce chemotherapy resistance [18-
21]. Nonetheless, GCs have been used in cancer therapy 
since the 1940s. Nowadays, they are commonly found 
in the regimens of acute lymphocytic leukemia, chronic 
lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s 
lymphoma, multiple myeloma [7, 8] and prostate cancer 
[18]. Furthermore, they are used as adjuvant therapy in 
the treatments of various solid tumors to avoid excessive 
immune reactions and healthy cell toxicity in response to 
chemotherapy, to reduce nausea and emesis, to decrease 
swelling, to inhibit tissue reaction (e.g. inflammation) 
against invasive tumor growth or as palliative treatment 
of metastasis-related pain [8]. The cancer-modulating 
mechanisms of GCs are not yet fully understood, but a 
variety of such mechanisms has been postulated and 
investigated [8, 18, 19, 59]. 
In hematological malignancies, the major effect 
of GCs is induction of apoptosis of cancer cells [5, 6]. 
The exact mechanism has not yet completely been 
clarified. Nevertheless, intervals of continuously 
administered steroids, e.g. dexamethasone, and sufficient 
levels of functionally receptive and active GR in 
malignant lymphoid cells are essential to reach therapy 
effectiveness. This evokes a culmination of genomic, 
including transactivation and transrepression, and non-
genomic regulatory events, suggesting the involvement 
of a complex crosstalk between GCs and diverse other 
signaling pathways [5]. GR transactivation is required 
for apoptosis via upregulating pro-apoptotic genes, such 
as Bim and suppressor of AP-1 regulated by interferon 
(SARI) [6, 62-65]. Other studies stress the importance of 
GC-induced transrepression of the nuclear factor κB (NF-
κB) and activator protein 1 (AP-1) as a driver of apoptosis, 
impairing transcription of pro-inflammatory cytokines, 
such as IL-6, anti-apoptotic genes, such as Bcl-xL, and 
cell cycle promoting genes, such as cyclin D1 [50, 51, 
62, 66]. Non-genomic mechanisms such as translocation 
of GR into mitochondria were shown to reduce the 
mitochondrial outer membrane potential, promoting the 
release of cytochrome C, a prerequisite for the activation 
of the intrinsic apoptotic pathway [56, 67]. Until today, 
combination of traditional chemotherapies and newer 
agents (such as proteasomal inhibitors) with GCs remain 
a cornerstone in the treatment of lymphoid malignancies, 
especially for multiple myeloma and acute lymphoblastic 
leukemia therapy [68-71].
During the treatment of breast cancer, GCs are often 
administrated as an adjuvant therapy to reduce the adverse 
effects of chemotherapy and to protect the normal tissue 
against the long-term effects of genotoxic drugs [72]. Yet, 
in 1958, an autopsy study on patients with disseminated 
breast carcinoma showed that 26% (8 of 31) of women 
who received glucocorticoid treatment developed spleen 
Table 1: The effect of glucocorticoids on different tumor entities.
Malignancy Effects of GCs Refs
Hematological malignancies Induction of apoptosis via upregulation of pro-apoptotic genes, 
transrepression of NF-κB and AP-1 and non-genomic mechanisms.
[5, 6, 63, 64, 67-71]
Breast cancer Depending on cell type and GR and ER status, inhibition of 
chemotherapy-induced apoptosis via inactivation of MAPKs, 
transrepression of certain genes and transactivation of DUSP1/
MKP1 and SGK-1.
[9, 76-79, 155]
Skin tumor Prevention of skin tumor promotion. Resistance to GCs in 
established papillomas and carcinomas.
[81-89]
Prostate cancer Progression inhibition in hormone-refractory prostate cancer via 
inhibition of adrenal androgen production and the modulation of 
gene expression.  Progression stimulation in tumors receiving anti-
androgen therapy via diminishing the efficacy of anti-androgen 
therapy and transactivation of pro-cell survival genes.
[18, 19, 90-95]
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metastases, whereas women who had not received the 
therapy, did not develop spleen metastases (0 of 16) 
[11, 13, 73]. This was confirmed by a following autopsy 
study on gastroduodenal metastases, where 29 out of 136 
patients (21%) who had received corticosteroids developed 
metastases to the gastroduodenal area as compared to 9 
out 68 patients (13%) of the control group [73, 74]. GCs 
can inhibit apoptosis in breast cancer cells in vitro and in 
vivo [75] . More specifically, they inhibit chemotherapy-
induced apoptosis, via GR-mediated inactivation of 
mitogen-activated protein kinases (MAPKs), GR-mediated 
inhibition of certain genes, including Insulin-like growth 
factor-binding protein 3 (IGFBP-3) and tissue plasminogen 
activator and GR-fueled increased expression of dual-
specificity phosphatase 1 (DUSP1)/mitogen-activated 
protein kinase phosphatase-1 (MKP1) and serum/
glucocorticoid regulated kinase 1 (SGK-1) [10, 76-79]. 
The latter mechanism suggests that transrepressive GC 
compounds lacking transactivation may remain effective 
while reducing adverse effects. Regardless of the negative 
impact of exogenous GC administration, GR expression 
itself is not a reliable prognostic factor for tumor size, 
stage and grade. Moreover, sustainable expression of 
GR has been associated with several beneficial outcome 
features, among which estrogen receptor, progesteron 
receptor, Forkhead Box A1, GATA -binding protein 3 and 
brain-expressed X-linked 1 (BEX1) expression [80]. 
In skin tumor models, induced by chrysarobin, 
7-bromomethylbenz[a]anthracene (BrMBA) or 
12-O-tetradecanoylphorbol-13-acetate (TPA), GCs can 
prevent skin tumor promotion in vitro and in vivo [81-86]. 
Furthermore, transgenic animals expressing high levels of 
GR in the skin seemed to be highly resistant to skin tumor 
development [83, 87]. However, several tumorigenic 
keratinocyte cell lines appeared functionally GC-resistant 
to GC-induced growth arrest, regardless of the high levels 
of GR mRNA and protein [88]. Moreover, established 
papillomas and carcinomas appear to be resistant to GCs 
[88, 89]. 
The role of GR in prostate cancer is rather 
ambiguous. On the one hand, GCs are often a part of 
complex chemotherapy in advanced hormone-refractory 
prostate cancer. Their anti-cancer effects are attributed 
primarily to their inhibitory effect on adrenal androgen 
Figure 2: Chemical structures of discussed GR-targeting compounds. Classical GR agonists such as dexamethasone and 
prednisolone have a steroidal skeleton. Selective GR agonists and modulators are divided in two categories: steroidal, RU24858 and 21OH-
6,19OP, and non-steroidal, avicin D and compound A, compounds.
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production. Recent evidence shows that GCs also 
directly target prostate cancer cells through modulation 
of the expression of genes regulating growth, apoptosis, 
inflammation, metastasis, differentiation, cell survival and 
angiogenesis [18, 19, 90-93]. On the other hand, prostate 
tumors that have received prolonged androgen receptor 
(AR)-blocking anti-androgen therapy (e.g. enzalutamide) 
display a relatively higher GR expression level which 
rather increases cell viability and facilitates progression 
in vivo [94, 95]. GR-mediated actions also diminish the 
efficacy of AR inhibition therapy and even stimulate the 
expression of pro-cell survival genes. In some prostate 
cancers anti-androgen resistance has been linked to 
upregulation of GR. Since GR and AR have partially 
overlapping target genes, upregulation of GR may restore 
the transcription of one or more AR target genes following 
AR inhibition therapy [94]. This puts forth the idea that 
whereas GR activation has a detrimental effect on AR 
signaling-deficient prostate cancer, it can also inhibit the 
progression of prostate cancers from androgen dependence 
to hormone resistance as long as AR is still functionally 
active. 
The effect of GCs on the efficiency of chemotherapy 
and radiotherapy is controversial. In several established 
cell lines as well as primary carcinoma cells from solid 
tumors (i.e. bone, brain, breast, cervix, melanoma and 
neuroblastoma) GCs could prevent chemotherapy-induced 
cell death and even promote proliferation [12, 75, 96-
110]. Also in the clinical setting, it has been observed that 
concomitant combination chemotherapy with GCs resulted 
in a worse outcome than single chemotherapy [111, 
112]. In radiotherapy mouse models, GCs could have an 
indirect positive effect on radiosensitivity via decreasing 
tumor oxygen consumption, and thereby enhancing tumor 
oxygenation [113]. Paradoxically, GC-induced resistance 
to radiotherapy [114] and GR antagonist-enhanced 
radiosensitivity have also been reported [115, 116].
SELECTIVE GLUCOCORTICOID 
RECEPTOR AGONISTS AND 
MODULATORS (SEGRAMS)
Selective glucocorticoid receptor agonists and 
modulators (SEGRAMs) are a class of compounds which 
act on GR in analogy to GC, yet affect GR-mediated 
gene expression in a different manner, skewing the bulk 
of gene expression modulation to either transrepression 
or transactivation, but with the intention to improve 
the therapeutic efficacy. Although in inflammatory 
afflictions, a new model balancing transrepression and 
transactivation more carefully is now appearing [3, 22, 
23], a few decades ago the key anti-inflammatory effect 
of GR was attributed to its transrepression mechanism 
[117-119], while the majority of GC-associated side 
effects was originally ascribed to GR transactivation 
[120]. This pharmacological model launched a series of 
compounds exerting primarily transrepressive effects of 
GR for treatment of inflammatory disorders [3]. As such, 
RU24858 [24], 21OH-6,19OP [25, 26], avicin D [27], 
compound A (CpdA) [28], (Figure 2) and many more [3, 
29] have been classified as SEGRAMs.
How shifting the balance to a relative preponderance 
in GR transactivation or GR transrepression affects 
therapeutic efficacy related to tumor development, 
tumor growth, tumor cell apoptosis or GC/GR-induced 
chemotherapy resistance is not completely clear yet. But 
since it is known that GR can affect malignancies in a 
stimulating and inhibiting manner (as discussed above), 
increased interest into whether SEGRAMs can skew the 
action radius of GR to solely tumor suppression spikes in 
literature.  
Evidence that GR transrepression and GR 
transactivation can be dissociated originates from a 
pioneering study with a GR dimerization mutant (GRdim) 
[117]. This mutant harboring a point mutation in the 
second zinc finger of the GR DNA-binding domain, has 
difficulties forming GR homodimers, which abrogates high 
affinity binding to GRE motifs at specific gene promoters. 
This abolishes to a large extent GR transactivation 
effects whereas transrepression capacity remains largely 
unaffected [121, 122]. In multiple myeloma, GRdim-
based experiments reveal a specific role for classic GR 
transactivation in GR-mediated apoptosis [123]. 
The well-known GR antagonist RU486 (also known 
as mifepristone), is incorporated into various cancer 
regimens because of its antineoplastic potential. However, 
RU486 is also a progesterone and androgen receptor 
antagonist, and most research attributes the antineoplastic 
effect to the antagonism of the progesterone receptor 
[124]. Yet, current findings question this hypothesis [125]. 
Since RU486 has an antagonistic effect and is not GR 
specific, it is not considered a SEGRAM.
Our review will particularly focus on RU24858, 
21OH-6,19OP, Avicin D and CpdA, as these are the 
only SEGRAMs, for which potential cancer-modulating 
properties have been reported so far. 
The underlying mechanism for differential GR 
regulation by SEGRAMs and GCs has not completely 
been resolved. CpdA [28], avicin D [27], RU24858 
[126] and 21OH-6,19OP [127] can instigate a GR 
translocation to the nucleus in analogy to classic GCs (e.g. 
dexamethasone), although potencies may vary [38, 128-
130]. Research indicates that CpdA [28], RU24858 [126] 
and 21OH-6,19OP [131] induce a different conformational 
change in GR than GCs do. In silico modeling maps 
CpdA [38], RU24858 [126] and 21OH-6,19OP [132] in 
the ligand-binding pocket of GR; whether this is also the 
case for avicin D is still unknown. However, even though 
the virtual docking studies show that CpdA could bind in 
the ligand-binding pocket, additional structural studies 
are still required. While CpdA promotes a monomeric GR 
conformation [127, 130], the compound 21OH-6,19OP 
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[25] drives GR to a dimeric formation, just as GCs do. 
It still needs to be investigated whether RU24858 and 
avicin D favor a predominately monomeric or dimeric GR 
conformation. The binding affinity to GR of the discussed 
SEGRAMs can be found in Table 2. 
Similarly to classical GCs, CpdA [133], avicin 
D [27], 21OH-6,19OP [25, 26], and RU24858 [134], 
efficiently downregulate the transcription of TNF-induced 
and NF-κB-dependent pro-inflammatory genes (e.g., IL-6, 
IL-8, E-selectin) (Figure 1) [28]. 
In contrast to classical GCs, CpdA [28], avicin 
D [27] and 21OH-6,19OP [132] do not stimulate 
endogenous GRE-dependent genes. This means that 
these compounds only exhibit transrepression effects, 
but lack transactivation capacity (Table 3) [27, 28]. This 
is in contrast to RU24858 [126] which still induces GR 
transactivation in selected cell types [135]. In mouse 
models, in contrast to dexamethasone, CpdA shows anti-
inflammatory effects and displays reduced GC side-effects 
because it does not induce hyperglycemia (potentially 
leading to diabetes) [28, 136], hyperinsulinemia [130] 
or skin atrophy [137] and does not elevate AST and 
ALT enzyme levels (which is a sign of liver toxicity) 
[138]. Endogenous cortisol levels are also maintained by 
CpdA [138]. Finally, whereas prolonged GC treatment 
frequently downregulates GR levels and contributes to 
the onset of GC resistance, prolonged CpdA treatment 
does not decrease GR levels, allowing sustainable 
anti-inflammatory effects [122, 128, 139]. Research 
investigating the in vivo adverse effects of the SEGRAMs 
RU24858, 21OH-6,19OP and avicin D is yet to be 
performed. How the SEGRAMs RU24858, 21OH-6,19OP, 
avicin D and CpdA affect the non-genomic effects of GR 
is currently still largely unknown. 
SEGRAMS’ CANCER-MODULATING 
POTENTIAL
Although the SEGRAMs discussed below are not 
the only SEGRAMs known to literature [3, 29], they are 
the only ones to our knowledge that have been evaluated 
for their cancer-modulating potential (Figure 3).
RU24858 
It has been revealed by competition assays in 
vitro that the SEGRA RU24858 binds GR with similar 
affinity as dexamethasone [24]. Since GCs can prevent 
skin cancer formation elicited by specific chemicals or 
ultraviolet radiation in animal models [82, 140, 141], 
the dissociated compounds RU24858 and RU24782 
have been investigated in this setting. In a SENsitivity to 
CARcinogenesis (SENCAR) mouse model classical GCs 
Table 2: Binding affinity of discussed SEGRAMs to GR.
SEGRAM-mediated binding to GR
SEGRAM GR, origin GR binding Ref
RU24858 A549 cells, h Ki = 110.0 ± 24.0 nM [134]
21OH-6,19OP rat thymus Kd = 125 nM (RBA for GR as compared to corticosterone) [26]
Avicin D A549 cells, h
competition for Dex 35% (with 5-fold excess); 85% (with 500-fold 
excess) [27]
CpdA L929sA, m IC50 = 6.4 nM (CI 1.9-20.5 nM) [28]
BWTG3, m Kd = 81.8 nM [156]
COS-1, s, TT hGR IC50 = 0.003 ± 0.004 nM
[157]
DU145 cells, h competition for Dex 85% (with 100-fold molar excess) [38]
Dexamethasone A549 cells, h Ki = 4,9 ± 1.3 nM [134]
L929sA, m IC50 = 25.9 nM (CI 7.9-84 nM) [28]
BWTG3, m Kd = 1.29 nM [156]
COS-1, s, TT hGR IC50 = 14 ± 4 nM [157]
Abbreviations: RBA, relative binding affinity; CI, confidence interval; h, human; m, murine; s, simian; TT, transiently transfected; IC50, concentration at 
which compound inhibited 50% of specific binding of labeled dexamethasone. 
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and the compound RU24858 were both able to prevent 
epidermal hyperplasia and proliferation elicited by 
exposure to tumor-promoting TPA. The anti-proliferative 
and anti-hyperplastic effects of RU24858 in these mice 
were weaker than that of the classic GCs. Furthermore, 
RU24858 was also able to reverse the induction of 
TPA-induced genes, associated in skin tumor promotion 
(such as c-Jun, COX-2 and iNOS) [31]. In contrast, the 
comparable compound RU24782, which has a thioether 
functional group instead of a nitrile functional group 
as compared to RU24858, failed to elicit anti-cancer 
activities [31]. The different behavior of these SEGRAs 
could be due to a varying inhibition of NF-κB and/
or a varying ability to interact with repressive histone 
deacetylases [31, 142-144]. 
21OH-6,19OP
21OH-6,19OP is a selective GR agonist, which 
lacks the bulky substituent at C-11, found in active 
GR antagonists [26, 145]. This compound is able to 
transrepress AP-1 and NF-κB pathways in COS-1, RAW 
264.7 and BHK cells, yet not in A549 lung cancer cells 
[25, 37, 132]. In the latter cells, 21OH-6,19OP was 
shown to block TNF-induced COX2 and IL-8 expression 
[37]. Furthermore, it is largely incapable of inducing 
transcription of GRE-regulated genes [25, 26] and, when 
incubated in combination with dexamethasone, it acts as 
an antagonist to GR transactivation [26]. These findings 
indicate that 21OH-6,19OP is a cell-specific, selective 
GR agonist. Noteworthy, 21OH-6,19OP is capable of 
upregulating DUSP1, most likely contributing to its 
cytokine-inhibiting capacities [37].
As it is known that GCs, administered for symptom-
reducing reasons, can induce chemoresistance in certain 
malignancies [11], SEGRAM-based research could 
shed light on the mechanistic 21OH-6,19OP basis of 
this phenomenon. 21OH-6,19OP could circumvent this 
mechanism as in vitro and in vivo research indicates that 
contrary to the classic GC dexamethasone, 21OH-6,19OP 
does not preclude cell death triggered by the anthracyclin 
doxorubicin in mammary tumor cells. Concomitantly, 
21OH-6,19OP does not avert paclitaxel-stimulated 
caspase-3 activation and does not stimulate anti-apoptotic 
BCL-XL isoform gene expression [37].
Avicin D
Avicin D [30] is a desert plant-derived triterpenoid 
saponin [32], with GR-mediated anti-inflammatory 
effects [27]. It has also been shown that avicin D induces 
apoptosis in a variety of human tumor cell lines, such 
as T-cell leukemia cells (Jurkat cells), breast cancer 
cells (MDA-MB-435), prostate cancer cells (PC3) and 
cutaneous T-cell lymphoma cells (CTCL) [27, 30, 32-36]. 
Contrary to its anti-inflammatory effects, current research 
indicates that avicin D’s cytotoxicity is GR-independent 
[27]. The underlying mechanism of apoptosis induction 
is most likely a direct effect of avicin D on mitochondrial 
bioenergetics which subsequently triggers the apoptosis 
cascade [33, 146, 147]. 
Compound A
Compound A is a desert plant-derived SEGRM 
that exhibits GR transrepression capacities, and lacks the 
ability to fuel classic GR transactivation. In malignant 
prostate, bladder, leukemia and multiple myeloma cell 
lines and primary leukemia cells, CpdA can induce 
apoptosis [38-42]. Contrary to avicin D, its pro-apoptotic 
and cytotoxic effects are reported to be partially GR-
dependent [38, 39, 41, 42]. 
In advanced prostate cancer, activation of the AR 
has a pro-tumorigenic effect, whereas exclusive activation 
of GR can have an anti-tumorigenic effect [18, 19, 90-
93]. The SEGRM CpdA can affect both of these steroid 
receptors in different cell lines, among which prostate 
cancer cells [38, 43]. Virtual docking studies showed 
that CpdA was able to bind the AR. However, CpdA was 
not able to compete for binding to the AR, in contrast to 
the androgen mibolerone. Nevertheless, CpdA induces 
the nuclear translocation of AR, but inhibited AR DNA 
binding and AR transcriptional activity [38, 43]. Thus, 
the effect of CpdA resembles the effect of anti-androgens, 
commonly used in the therapy of prostate cancer [43]. 
CpdA shifts the activity of GR towards transrepression, 
theoretically resulting in the inhibition of pro-
proliferative and anti-apoptotic gene expression. However, 
experimental evidence to substantiate this is currently 
lacking. Remarkably, CpdA seems able to upregulate the 
protein levels of pro-apoptotic Bim and tumor suppressor 
p53 in both CEM and K562 leukemia cells [40]. 
CpdA’s selective GR actions and to a lesser extent its 
antagonistic AR actions also contribute to the compound’s 
Figure 3: SEGRAM-triggered mechanisms in cancer. 
SEGRAMs have anti-inflammatory properties, can inhibit 
proliferation, migration and invasion, and can induce apoptosis 
of cancer cells. However, the specific action mechanism depends 
on the SEGRAM itself and on the tissue type.
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ability to inhibit bladder cancer cell proliferation, colony 
formation, cell migration and invasion, and to increase 
cell cycle arrest and apoptosis [41]. The combination of 
AR blockage and GR-mediated transrepression resulted 
in an inhibition of prostate tumor growth in vitro [38] 
and bladder cancer cell xenograft growth in vivo [41]. 
Furthermore, CpdA induced increased caspase activation 
and PARP cleavage in these prostate cancer cells [38]. 
Currently, the proteasomal inhibitor bortezomib is 
often used in therapy for lymphomas and myelomas [148]. 
The combination of bortezomib and GCs has been proven 
to act synergistic in hemoblastoses [149]. This synergistic 
effect may be explained in several different ways. The 
proteasome inhibitor prevents GR cleavage, consequently 
GR levels rise and GR activity is reinforced. In addition, 
GCs enhance the expression of proteins implicated in the 
development of ER stress [40], and excessive ER stress 
induces apoptosis and sensitizes cells to bortezomib-
induced apoptosis [150]. CpdA treatment had a more 
prominent cytostatic and apoptotic effect on leukemia 
cells as compared to treatment with the GC fluocinolone 
acetonide. Furthermore, the combined treatment with 
bortezomib and CpdA showed that CpdA potentiated the 
cytotoxic effect of bortezomib [40]. 
In breast cancer, Chen et al. recently discovered that 
dexamethasone, but not CpdA treatment clearly protects 
triple negative breast cancer cells (MDA-MB-231) from 
paclitaxel-induced growth inhibition [44]. Moreover, 
Chip-exo-based studies confirm that Dex-liganded, but 
not CpdA-liganded, GR can bind to a single GRE, which 
drives the expression of pro-tumorigenic genes. From the 
transrepression perspective, AP-1 and NF-kB-enriched 
motifs in triple negative breast cancer cells do not attract 
a tethering CpdA-liganded GR. Actually CpdA alters the 
expression of only a small number of genes that are not 
involved in carcinogenesis and therapy resistance [44]. 
These findings suggest that tweaking the action radius of 
GR may lead to a safer coadjuvant for chemotherapy for 
breast cancer.
In contrast to classic GCs and RU24858 [31], 
CpdA was not able to inhibit TPA-induced skin epidermal 
thickening and proliferation. Moreover, it even increased, 
yet to a lesser extent than TPA, the epidermal thickness 
and proliferation of keratinocytes in an in vivo model of 
SENCAR mice [45]. This effect can possibly be explained 
by the fact that CpdA-bound GR does not transrepress 
AP-1-regulated genes in particular cell types, and as 
such may be less effective in suppressing transcription of 
tumorigenesis-associated genes c-Jun, COX-2, and IL-6 
[133]. Yet, CpdA was able to decrease the expression 
of the p50 subunit of NF-κB in these SENCAR mice. 
Of special note, since NF-κB is constitutively activated 
in 7,12-dimethylbenz[a]anthracene (DMBA)/TPA-
promoted mouse skin tumors, partially due to an increase 
in expression/activation of p50, this pathway could have 
an interesting anti-tumoral potential [45]. 
Furthermore, the effect of CpdA was recently also 
investigated on cancer-surrounding cells, namely colon 
cancer-derived myofibroblasts, which influence cancer 
cells via cell-to-cell or paracrine signaling. This research 
revealed that in comparison to dexamethasone, CpdA only 
had minor impact on gene expression and protein levels of 
cancer-promoting factors [128]. 
DISCUSSION
Although the cell type-specific anti-cancer potential 
of GCs involves inhibition of growth and induction of 
apoptosis, the mechanism by which GCs are able to do this 
has not been completely elucidated. Further research with 
currently available anti-inflammatory SEGRAMs, under 
clinical evaluation [3], will allow to dissect the mechanism 
of action of GR in neoplastic tissue. This will entail the 
design of SEGRAMs with very specific mechanisms of 
action to fight against cancer. 
Despite its widespread use, chronic exposure to GCs 
in cancer treatments is severely limited by the vast range 
of side effects it induces or the development of therapy 
resistance [2]. Therefore, the development of clinically 
more selective compounds that exert the activation or 
inhibition of a subset of pathways may result in a more 
focused anti-cancer action, reduced risk of therapy 
resistance, but also a significant reduction in side effects 
and thus more comfort for the patient. Along the same line, 
the development of selective estrogen receptor modulators 
and selective androgen receptor modulators has yielded 
compounds with improved anti-cancer action and reduced 
side effects. Their selective action radius has allowed 
these compounds to be used also in primary prevention 
regimens against cancer (e.g. tamoxifen in breast cancer) 
[151], besides their classical use in integral cancer 
therapy, like chemotherapeutic agents such as cisplatin or 
paclitaxel. Spatiotemporal delivery restrictions could aid 
to confine the compounds’ actions even further and thus 
limit the side effect profile and increase its efficiency. The 
development of a liver-specific GR antagonist A-348441 
(now called KB3305) with a clinical proof-of-concept 
shows that it is feasible to develop tissue- or organ-specific 
GR-targeting compounds [152]. In the framework of 
solid tumors and the associated leaky vasculature, recent 
work in metastatic prostate cancer bone lesions shows 
that liposomal encapsulated dexamethasone is delivered 
to these malignant bone lesions and sometimes inhibits 
in vivo tumor growth more efficiently than systemic 
administration of dexamethasone [153]. Also the recent 
research proving the anti-cancer effect of cationic lipid-
conjugated hydrocortisone, which selectively targets 
cancer cells endorses the possibility of cell-type specific 
GR-targeting compounds [154].
In conclusion, combining selective GR modulator 
compounds, with innovative tissue- or cell- specific 
delivery methods may allow to further optimize 
Oncoscience196www.impactjournals.com/oncoscience
therapeutic efficacy and reduce adverse GC-associated 
side effects. Further investigation of selective modes 
of action of GR should allow further development 
of GR dependent anti-cancer compounds for various 
malignancies, with improved specificity and optimized 
therapeutic window. 
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